Expand ABVX Menu
ABVX MENU

ABVX Latest Press Releases

-- September 30, 2026 --

Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026 Globe Newswire 4:05 PM

-- September 21, 2026 --

Abivax Presents Business Updates and First Half 2026 Financial Results Globe Newswire 4:05 PM

-- July 30, 2026 --

Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod Globe Newswire 4:05 PM

-- July 23, 2026 --

Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments Globe Newswire 4:05 PM

-- July 6, 2026 --

Abivax Announces Closing of $920 Million Public Offering Globe Newswire 4:05 PM

-- July 2, 2026 --

Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M ( EUR 807M) Globe Newswire 2:00 AM

-- July 1, 2026 --

Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M ( EUR 702M) Public Offering of American Depositary Shares Globe Newswire 9:06 AM
Abivax announces trading resumption of its ordinary shares on Euronext Paris Globe Newswire 8:56 AM
Abivax Announces Pricing of Oversubscribed and Upsized $800M ( EUR 702M) Public Offering of American Depositary Shares Globe Newswire 8:37 AM
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris Globe Newswire 1:30 AM

-- June 30, 2026 --

Abivax Announces Launch of Public Offering of American Depositary Shares Globe Newswire 4:45 PM

-- June 29, 2026 --

Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database Globe Newswire 4:05 PM

-- June 10, 2026 --

ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm Globe Newswire 10:15 AM

-- June 9, 2026 --

ABVX DEADLINE: The Gross Law Firm Reminds ABIVAX Societe Anonyme Investors of Upcoming Securities Class Action Deadline PRNewswire 9:01 AM

-- June 3, 2026 --

ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm Business Wire 8:53 PM

-- June 2, 2026 --

Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX) PRNewswire 9:20 PM

-- June 1, 2026 --

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis Globe Newswire 4:05 PM

-- May 28, 2026 --

Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation Globe Newswire 8:35 AM

-- May 22, 2026 --

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis Globe Newswire 4:05 PM
Market Data Delayed 15 Minutes